| Drug Name |
Hydralazine |
| Drug ID |
BADD_D01081 |
| Description |
Originally developed in the 1950s as a malaria treatment, hydralazine showed antihypertensive ability and was soon repurposed.[A186841] Hydralazine is a hydrazine derivative vasodilator used alone or as adjunct therapy in the treatment of hypertension and only as adjunct therapy in the treatment of heart failure.[A186820,L8782,L8785] Hydralazine is no longer a first line therapy for these indications since the development of newer antihypertensive medications.[T691]
Hydralazine hydrochloride was FDA approved on 15 January 1953.[L8779] |
| Indications and Usage |
Hydralazine is indicated alone or adjunct to standard therapy to treat essential hypertension.[L8782] A combination product with isosorbide dinitrate is indicated as an adjunct therapy in the treatment of heart failure.[L8785] |
| Marketing Status |
approved |
| ATC Code |
C02DB02 |
| DrugBank ID |
DB01275
|
| KEGG ID |
D08044
|
| MeSH ID |
D006830
|
| PubChem ID |
3637
|
| TTD Drug ID |
D0K1XK
|
| NDC Product Code |
Not Available |
| UNII |
26NAK24LS8
|
| Synonyms |
Hydralazine | Hydrallazin | Hydrazinophthalazine | Apressin | Nepresol | Hydralazine mono-Hydrochloride | Hydralazine mono Hydrochloride | mono-Hydrochloride, Hydralazine | Apressoline | Apresoline | Hydralazine Hydrochloride | Hydrochloride, Hydralazine |
